Market cap
₹2,255 Cr
Recently Viewed
Clear AllNSE: FKONCO | BSE: 532545
₹132.50
₹0.45
(0.34%)
As on 02-Jan-2014IST
Market cap
₹2,255 Cr
Revenue (TTM)
₹813 Cr
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹75 Cr
ROE
5.5 %
ROCE
7.3 %
Industry P/E
--
EV/EBITDA
20.5
Debt to Equity
0.1
Book Value
₹29.4
EPS
₹1.6
Face value
1
Shares outstanding
170,247,857
CFO
₹-69.41 Cr
EBITDA
₹851.39 Cr
Net Profit
₹-226.20 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
| 0.5 | 2.0 | 3.5 | 24.2 | 3.6 | 28.0 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
BSE Healthcare#
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
132.5 | 2,254.9 | 813.1 | 75.1 | -22.7 | 5.5 | -- | 3.6 |
| 2,594.1 | 21,258.3 | 1,339.4 | 356.4 | 33.2 | 23.2 | 59.7 | 12.9 | |
| 483.3 | 18,476.1 | 2,051.5 | 180.5 | 11.6 | 7.7 | 91.6 | 4.8 | |
| 699.7 | 17,327.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 29.1 | 3.4 | |
| 1,095.8 | 19,627.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,738.1 | 19,938.7 | 1,419.3 | 20.1 | 8.4 | 0.5 | 991.9 | 3.4 | |
| 161.9 | 21,520.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 970.0 | 16,018.9 | 1,284.3 | 134.4 | -- | 30.7 | 119.2 | 13.1 | |
| 467.7 | 18,887.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.6 | 3.9 | |
| 1,395.6 | 22,661.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1030.1 | 4.9 |
No Review & Analysis are available.
--
Incorporated
2003
Chairman
--
Managing Director
Arvind Kumar Sharma
Group
Fresenius Kabi Oncology - MNC
Headquarters
New Delhi, Delhi
Website
Looking for more details about Fresenius Kabi Oncology Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Fresenius Kabi Oncology Ltd is ₹132.50 (NSE) and ₹132.45 (BSE) as of 02-Jan-2014 IST. Fresenius Kabi Oncology Ltd has given a return of 3.65% in the last 3 years.
Since, TTM earnings of Fresenius Kabi Oncology Ltd is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Fresenius Kabi Oncology Ltd are Rs -- and Rs -- as of 03-May-2026.
Fresenius Kabi Oncology Ltd has a market capitalisation of ₹ 2,255 Cr as on 02-Jan-2014. As per SEBI classification, it is a company.
Before investing in Fresenius Kabi Oncology Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.